The effects of the high-dose WJHL group are superior to those of the leflunomide group, which indicate that both of leflunomide and WJHL groups could decrease the levels of TNF-α, IL-1β, IL-6, and IL-17A and increase the level of OPG to treat RA. The gene discussed is TNFRSF11B; the disease is rheumatoid arthritis.